focus -WSS

focus

author：explore 2025-09-30 00:09:46 - browse：33

Fran van Delft for Galapagos

Seeking to differentiate itself from other makers of CAR-T cancer therapies, Galapagos NV on Wednesday announced it had struck a deal with Blood Centers of America to open up dozens of manufacturing sites for its cell-based medicines around the U.S.

Galapagos said it will rely on the partnership, the financial terms of which were not disclosed, as it moves its CAR-Ts for different cancers into pivotal studies and could also help launch those medicines should they win approval. The Belgian company framed the collaboration as one that could help overcome the limitations that have held back access to existing CAR-T therapies from other companies.

CAR-Ts have proven to be potent treatments for certain cancers, but they are complicated medicines to make. Immune cells have to be removed from a patient, shipped to specialty sites, where they’re engineered with cancer-killing abilities, and then returned to the hospital for infusion back into patients. The process, which can take weeks if not months, has put a crunch on the number of patients companies and hospitals are able to treat.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： WATCH: Why do bright lights make us see spots?

leisure time

WSS

A common UTI test for kids haunts adults as a traumatic 'nightmare'

Private equity could exacerbate cardiology's overuse problem, experts fear

Bernie Sanders bashes nonprofit hospitals over their tax breaks

FDA panel endorses Alnylam’s heart drug — after picking it apart

Better Therapeutics data on benefit with GLP

Medicare to cover more brain scans related to Alzheimer’s drugs

hotspot

focus

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

leisure time

Anesthesiologist group: stop taking Ozempic before surgery

Long Covid needs a new name — and a new frame

After affirmative action ruling, medical educators look to 'holistic review'

Researchers CRISPR chickens in bid to protect them from bird flu

Novavax promises a turnaround & Lilly roils the obesity market

Takeaways from AdvaMed, the largest medical devices conference

Medical records are filled with copy

How clinical AI models' predictive power can degrade over time

Medicare proposal to cover medical devices draws a mixed reaction

Peter Marks talks Operation Warp Speed for Rare Diseases

focus

Researchers CRISPR chickens in bid to protect them from bird flu

PEPFAR is under serious threat — and so is global health

Private equity could exacerbate cardiology's overuse problem, experts fear

A common UTI test for kids haunts adults as a traumatic 'nightmare'

European regulators consider appeal over Amylyx ALS drug

How doctors and nurses shape Google's AI

hotspot

leisure time

Wikipedia

knowledge